<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11860340</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.238</article-id><article-id pub-id-type="other">O0120</article-id><article-id pub-id-type="pii">S0924933824002384</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>Oral Communication</subject></subj-group></article-categories><title-group><article-title>Impact of Antidepressant Treatment on Fibronectin Levels in Patients with Depression and Chronic Heart Failure</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sikora</surname><given-names>A. K.</given-names></name><xref rid="aff0378" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0099" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fedorov</surname><given-names>S.</given-names></name><xref rid="aff0379" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff0378">
<sup>1</sup>Psychiatry, <institution>Narcology and Medical Psychology</institution></aff><aff id="aff0379">
<sup>2</sup><institution>Ivano-FrankIskenderun National Medical University</institution>, <city>Ivano-Frankivsk
</city>, <country>Ukraine</country></aff><author-notes><corresp id="cor0099"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="213">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S95</fpage><lpage>S96</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824002384a.pdf"/><abstract><sec id="sec0593"><title>Introduction</title><p>Inflammation has emerged as a critical factor in the pathophysiology of both depression and chronic heart failure (HF). Chronic heart failure, a complex clinical syndrome, is often accompanied by a state of heightened inflammation, with elevated levels of proinflammatory markers. Likewise, depression, a prevalent comorbidity in HF patients, has been intricately linked to inflammation, with evidence suggesting a bidirectional relationship.</p></sec><sec id="sec0594"><title>Objectives</title><p>This study aimed to evaluate the effect of antidepressant treatment on plasma fibronectin levels in patients with comorbid depression and chronic heart failure.</p></sec><sec id="sec0595"><title>Methods</title><p>We enrolled a total of 113 patients with HF, all of whom had comorbid depression. The patients were divided into two groups based on the antidepressant treatment they received: Group 1 (n = 78) received vortioxetine, and Group 2 (n = 35) received sertraline. Before initiating treatment and after 6 months, we measured fibronectin levels in the patients&#x02019; plasma.</p></sec><sec id="sec0596"><title>Results</title><p>The study revealed a significant difference in the effects of the two antidepressants on fibronectin levels. Patients treated with vortioxetine demonstrated a substantial reduction in fibronectin levels post-treatment, with an approximate threefold decrease compared to the pre-treatment levels (pre-treatment value &#x000b1; standard deviation) &#x003bc;g/ml to (post-treatment value &#x000b1; standard deviation) &#x003bc;g/ml, (p&#x0003c;0.05). Conversely, patients treated with sertraline experienced a comparatively lesser reduction in fibronectin levels, with a change from (pre-treatment value &#x000b1; standard deviation) &#x003bc;g/ml to (post-treatment value &#x000b1; standard deviation) &#x003bc;g/ml (p&#x0003c;0.05).</p></sec><sec id="sec0597"><title>Conclusions</title><p>This study highlights the considerable impact of vortioxetine on fibronectin levels in patients with comorbid depression and chronic heart failure, resulting in a significant reduction. In contrast, sertraline&#x02019;s effect on fibronectin levels, while present, is notably less pronounced. The study emphasizes the potential therapeutic benefit of vortioxetine in cardiac remodeling associated with depression in patients with chronic heart failure, underscoring the need for further research and exploration.</p></sec><sec id="sec0598"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>